Vimentin (VIM)

Overview

VIM encodes vimentin, a type III intermediate filament protein that is widely used as a marker of mesenchymal cell states. In normal biology, vimentin contributes to cytoskeletal organization, cell shape, mechanical resilience, migration, and intracellular scaffolding. Because of these functions, its expression is often associated with cells undergoing epithelial to mesenchymal transition (EMT), a process in which epithelial cells acquire more motile, invasive, and fibroblast-like properties.

In biomedical research, vimentin is frequently studied as both a phenotypic marker and a functional participant in disease processes. It is especially prominent in cancer biology, where increased vimentin expression is commonly linked to invasive behavior, metastatic potential, and partial EMT states. It is also investigated in non-malignant contexts, including renal injury and fibrotic remodeling, and in neuroinflammatory disease mechanisms where modified forms of vimentin may influence immune signaling.

Recent Publications Focus

• 2026-06-19 — Irbesartan and high-glucose-induced EMT in HK-2 cells.
  This study examined epithelial-mesenchymal transition in HK-2 renal tubular epithelial cells under high-glucose conditions and assessed the effects of irbesartan. The authors measured mRNA and protein expression of NLRP3, caspase-1, NF-κB p65, α-SMA, vimentin, and N-cadherin by RT-qPCR and western blotting, linking VIM to an EMT/inflammatory phenotype in a setting involving the NLRP3 inflammasome and CASP1-related signaling 42318962Jun.

• 2026-06-09 — Astrocytic PAD2, citrullinated vimentin, and amyloid pathology.
  In an Immunity study focused on Alzheimer’s disease, PAD2 was shown to convert astrocytic vimentin into citrullinated vimentin (Cit-Vim175/184). This finding connects VIM to post-translational modification in astrocytes and suggests a mechanistic link between citrullinated vimentin, microglia activity, and exacerbation of amyloid pathology 41962542Apr.

• 2026-05-27 — Primary carcinoma of the rete testis in a Nellore bull.
  In this veterinary pathology report, neoplastic cells showed marked and diffuse immunostaining for vimentin and cytokeratin, while not staining for CD31. The result supports the use of vimentin as an immunohistochemical marker in tumor characterization and differential diagnosis 42201564May.

• 2026-05-20 — Alginate-derived carbonized nanogels and tumor metastasis.
  This study reported that Alg-CNGs attenuated metastasis in 4T1 triple-negative breast cancer cells by suppressing EMT. Specifically, the nanogels increased E-cadherin and decreased N-cadherin and vimentin, with reduced migration and invasion and disruption of actin organization and adhesion-related dynamics. These findings place VIM within a broader EMT program relevant to metastatic behavior 42167427May.

• 2026-04-22 — Müller cell membrane biomimetic nanocarriers and VIM-mediated recognition.
  This work described biomimetic nanocarriers that promoted efficient Ascl1 delivery through vimentin (VIM)-mediated specific cellular recognition. Here, VIM was used as a functional determinant of cell targeting, illustrating a non-canonical role for vimentin in nanocarrier-cell interactions and delivery specificity 42031060Apr.

• 2026-04-17 — TMEM45B and liver cancer progression.
  In a study of liver cancer progression, EMT-related changes were evaluated by immunofluorescence staining of vimentin and E-cadherin. VIM served as a readout of EMT status in the context of met signaling activation, reinforcing its role as a marker of phenotypic plasticity in cancer 41998230Apr.

• 2026-03-30 — DNA self-assembly platform for lung cancer metastasis evaluation.
  The constructed DNA-N@Ag+@PIX system employed vimentin as a marker in a biosensor-based strategy for evaluating lung cancer metastasis. This application highlights VIM’s utility in diagnostic and analytical platforms aimed at detecting metastatic phenotypes 41932242Apr.

What Changes, What Holds

1. Vimentin remains a readout of EMT even in inflammatory renal injury models
REINFORCES High-glucose HK-2 work keeps VIM in the established frame of epithelial-to-mesenchymal transition and phenotypic plasticity, now alongside NLRP3/CASP1-linked inflammatory signaling 42318962Jun. It does not displace the baseline account of vimentin as an EMT-associated marker and functional participant; instead, it sharpens the renal-injury context in which that association is being tracked.

2. Astrocytic vimentin can be post-translationally modified into a disease-linked form
NEW DIRECTION PAD2-driven citrullination adds a role not covered by the Overview: VIM is not just a mesenchymal marker or scaffolding protein here, but a substrate whose modified astrocytic form may influence microglia and amyloid pathology 41962542Apr. That extends the baseline into neurodegenerative mechanism, but it does not contradict the established EMT/cytoskeletal account.

3. Vimentin continues to serve as a diagnostic marker in tumor pathology
REINFORCES Diffuse immunostaining in a veterinary carcinoma mainly confirms the long-standing use of VIM in immunohistochemical tumor characterization and differential diagnosis 42201564May. The finding is specific to one neoplasm, but the class of claim is already well established in the Overview, so this adds an example rather than a new role.

4. Lower vimentin tracks reduced metastatic EMT behavior
REINFORCES Suppression of vimentin alongside restored epithelial markers fits the baseline view that VIM rises with invasive, mesenchymal-like cancer states 42167427May. The nanogel context is new, but the underlying claim is not: vimentin remains a marker and participant in metastatic EMT rather than a reversed or opposing signal.

5. Vimentin can be exploited as a cell-recognition handle for delivery systems
NEW DIRECTION Biomimetic nanocarrier targeting through VIM-mediated recognition adds a functional use not described in the Overview, which focuses on cytoskeletal, EMT, and disease-marker roles 42031060Apr. This does not overturn the baseline, but it does broaden vimentin from a state marker to a targeting determinant in engineered delivery.

6. Vimentin still indexes EMT status in liver cancer progression
REINFORCES Immunofluorescent vimentin readout in liver cancer simply extends the established cancer-biology use of VIM as a marker of phenotypic plasticity and invasive transition 41998230Apr. The met-linked context is additional detail, not a change in what vimentin is understood to signify.

7. Vimentin is being repurposed as a metastasis-detection signal in biosensor platforms
NEW DIRECTION Using VIM in a DNA-based analytical system adds a diagnostic engineering role that the Overview does not cover 41932242Apr. The baseline already supports vimentin as a marker of metastatic phenotypes, but this work shifts the emphasis toward assay design and detection rather than biology alone.

Overview update candidates: astrocytic PAD2-mediated citrullination of vimentin in Alzheimer’s-related pathology; vimentin-mediated cellular recognition for nanocarrier targeting; vimentin use in biosensor-based metastasis detection.